Protocol Ledger

NCT03726853 · Phase II · COMPLETED

The Clinical Trial to Evaluate the Efficacy and Safety of CKD-497

Interventional Phase II clinical trial protocol NCT03726853 sponsored by Chong Kun Dang Pharmaceutical in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-29 Enrollment: 220 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03726853
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)220 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03726853
Protocol FieldVerified Registry Value
NCT IdentifierNCT03726853
Consolidated Lead SponsorChong Kun Dang Pharmaceutical
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment220 participants (ACTUAL)
Registered Start Date2018-05-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03726853
Hospital Research SiteLocationSite Profile
Ulsan University HospitalUlsan, South KoreaOpen Hospital Dossier ->
Konkuk University Medical CenterSeoul, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI